Skip to main content
  • EN
  • FI
  • SV
Login

Main navigation

  • About FinnGen
    • Summary & Goals
      • Goals
      • FinnGen 1-2
      • FinnGen 3 (2023-2027)
    • Consortium
      • Partners
      • Funding
      • Governance
      • Steering Committee Members
      • Scientific Committee Members
      • Teams
      • Collaboration
    • Impact
      • National Impact
      • National Research Network
      • Open Science
      • Research Highlights
    • Why Finland?
      • Biobank Network
      • Legislative Review
      • National Registries
      • Population Genetic History
      • Industry partners
    • Mediabank
  • For Researchers
    • Research Activities
      • Core Analyses
      • Disease Task Forces
      • Expansion Areas
      • Global Initiatives
    • Cohort and Data
      • Register Data
      • Basic Characteristics
      • Clinical Endpoints
      • Genetic Data
      • Laboratory Values
      • Other Phenotype Data
      • Recruitment
      • Other Biological Data
      • Data Available
    • Accessing Data, Results & Tools
      • Access results
      • Computing environment
      • How we collaborate
      • Partner researchers
      • Public data releases
      • Tools
    • Publications
    • Researcher FAQ
  • For Participants
    • Participation
      • Study Participants
      • Biobanks' Role in FinnGen
      • Biobank Contact Information
      • Recall Studies
      • Questions and answers
    • Data Protection and Security
      • Data Protection
      • Data Security
      • Sample & Data Flow
      • Data Protection Statement
    • Significance
      • Videos
  • News
  • EN
  • FI
  • SV

Links

  • PheWeb
  • Risteys
  • Meta-analysis Pheweb (FG-MVP-UKBB)
  • FinnGen handbook
  • Meta-analysis Pheweb (FG-UKBB)
  • Coding variant browser
  • Endpoint Browser
  • FinnGen GITHUB
  • LAVAA volcano plot
  • Multiple Manhattan Plot
  • Variant Cluster Corrector
  • Variant Cluster Call Corrector
Breadcrumb
  1. Home

Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:53
  • Read more about Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study

Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:44
  • Read more about Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization

Uncovering leading compounds for alzheimer’s disease treatment: mendelian randomization and virtual screening insights into plasma protein modulation

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:40
  • Read more about Uncovering leading compounds for alzheimer’s disease treatment: mendelian randomization and virtual screening insights into plasma protein modulation

Warfarin use and vestibular dysfunction insights from NHANES data, network pharmacology, Mendelian randomization, and molecular docking

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:34
  • Read more about Warfarin use and vestibular dysfunction insights from NHANES data, network pharmacology, Mendelian randomization, and molecular docking

Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:11
  • Read more about Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis

Appraising the causal role of cathepsins in genitourinary carcinoma: a two-sample mendelian randomization and prospective study based on 36,225 individuals

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:07
  • Read more about Appraising the causal role of cathepsins in genitourinary carcinoma: a two-sample mendelian randomization and prospective study based on 36,225 individuals

Exploring the association between 91 circulating inflammatory proteins and the risk of carcinoid syndrome: a Mendelian randomization analysis

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 15:03
  • Read more about Exploring the association between 91 circulating inflammatory proteins and the risk of carcinoid syndrome: a Mendelian randomization analysis

Exploring the causal relationship between vitiligo and psoriasis: a bidirectional Mendelian randomization analysis

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 14:46
  • Read more about Exploring the causal relationship between vitiligo and psoriasis: a bidirectional Mendelian randomization analysis

Genetic effects of circulating hormone and proteome on amyotrophic lateral sclerosis identified by Mendelian randomization

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 14:41
  • Read more about Genetic effects of circulating hormone and proteome on amyotrophic lateral sclerosis identified by Mendelian randomization

Monocyte CCL2 signaling possibly contributes to increased asthma susceptibility in type 2 diabetes

Submitted by Frida Mäkelä on Mon, 07/14/2025 - 14:36
  • Read more about Monocyte CCL2 signaling possibly contributes to increased asthma susceptibility in type 2 diabetes

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Current page 104
  • Page 105
  • Page 106
  • Page 107
  • Page 108
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Contact us

Contact person
finngen-info@helsinki.fi
Follow us on Bluesky
@finngen.bsky.social

Lead organisations

The University of Helsinki is the organization responsible for the FinnGen research project. The Finnish consortium partners include all Finnish public biobanks and their background organisations, so the project covers the whole of Finland. All partners are listed on this page.

About the website

Accessibility statement